Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

CD20-targeted Polypeptide TRU-015

A proprietary antibody-based single-chain polypeptide with B cell-depleting activity. Significantly smaller than a whole antibody, CD20-targeted polypeptide TRU-015 binds specifically to the B cell-specific cell surface antigen CD20 with full immunoglobulin Fv fragment-type target binding activity and full immunoglobulin Fc fragment-type effector function. This agent transiently depletes CD20-bearing B cells by inducing B-cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) and B-cell apoptosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:TRU-015
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search